Legal & General Group Plc lowered its position in Versartis, Inc. (NASDAQ:VSAR) by 1.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,372 shares of the biopharmaceutical company’s stock after selling 91 shares during the period. Legal & General Group Plc’s holdings in Versartis were worth $156,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Sphera Funds Management LTD. increased its position in shares of Versartis by 20.0% in the first quarter. Sphera Funds Management LTD. now owns 300,000 shares of the biopharmaceutical company’s stock worth $6,405,000 after buying an additional 50,000 shares during the last quarter. State Street Corp increased its position in shares of Versartis by 17.5% in the fourth quarter. State Street Corp now owns 445,716 shares of the biopharmaceutical company’s stock worth $6,638,000 after buying an additional 66,450 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of Versartis during the first quarter worth $563,000. Bank of New York Mellon Corp raised its stake in shares of Versartis by 21.1% in the first quarter. Bank of New York Mellon Corp now owns 164,247 shares of the biopharmaceutical company’s stock worth $3,506,000 after buying an additional 28,666 shares during the period. Finally, Oxford Asset Management raised its stake in shares of Versartis by 240.9% in the first quarter. Oxford Asset Management now owns 124,744 shares of the biopharmaceutical company’s stock worth $2,663,000 after buying an additional 88,151 shares during the period. 77.23% of the stock is currently owned by institutional investors and hedge funds.

Versartis, Inc. (NASDAQ:VSAR) traded down 1.46% during midday trading on Tuesday, reaching $16.85. 13,554 shares of the company’s stock traded hands. Versartis, Inc. has a 1-year low of $9.05 and a 1-year high of $24.00. The company’s market capitalization is $599.49 million. The firm’s 50 day moving average price is $17.81 and its 200-day moving average price is $18.03.

Versartis (NASDAQ:VSAR) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.20. Equities analysts expect that Versartis, Inc. will post ($3.25) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/versartis-inc-vsar-stake-lowered-by-legal-general-group-plc/1491592.html.

VSAR has been the topic of a number of research analyst reports. Canaccord Genuity set a $28.00 price objective on shares of Versartis and gave the company a “buy” rating in a report on Sunday, May 28th. Piper Jaffray Companies set a $26.00 price objective on shares of Versartis and gave the company a “buy” rating in a report on Tuesday, June 27th. Cantor Fitzgerald set a $34.00 price objective on shares of Versartis and gave the company a “buy” rating in a report on Thursday, July 27th. BidaskClub raised shares of Versartis from a “hold” rating to a “buy” rating in a report on Monday, July 24th. Finally, Zacks Investment Research raised shares of Versartis from a “sell” rating to a “hold” rating in a report on Thursday, June 29th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. Versartis presently has a consensus rating of “Buy” and an average price target of $25.43.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Want to see what other hedge funds are holding VSAR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Versartis, Inc. (NASDAQ:VSAR).

Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.